Leukemia Sel Plasma Primer

Authors

  • Dian Sukma Hanggara Laboratorium Patologi Klinik Universitas Brawijaya
  • Budiman Budiman Laboratorium Patologi Klinik Universitas Brawijaya

DOI:

https://doi.org/10.21776/ub.jkb.2017.029.03.17

Keywords:

Leukemia sel plasma, mieloma multipel, sel plasma

Abstract


Leukemia sel plasma merupakan penyakit yang langka, hanya sekitar 2-4% dari plasma cell dyscrasia. Manifestasi klinis leukemia sel plasma primer lebih agresif dibandingkan dengan mieloma multipel. Artikel melaporkan kasus pasien laki-laki berumur 59 tahun datang ke Instalasi Gawat Darurat (IGD) dengan keluhan badan lemah dan nyeri pada kedua kaki sejak sebulan yang lalu dan memberat seminggu terakhir. Pasien juga mengeluhkan nyeri punggung, mual, penurunan nafsu makan, dan penurunan berat badan. Pemeriksaan fisik menunjukkan penurunan respon motorik pada ekstrimitas bawah. Pemeriksaan laboratorium menunjukkan anemia normokrom normositik, leukositosis dengan 60% sel plasma, trombositopenia, hipoglobulinemia, azotemia, hiperkalsemia, hiperfosfatemia, hiponatremia, hipogamaglobulinemia pada elektroforesis protein, dan 50% sel plasma pada aspirasi sumsum tulang. Bone survey menunjukkan proses metastasis pada tulang. Diagnosis leukemia sel plasma primer ditegakkan oleh adanya lebih dari 20% sel plasma atau jumlah absolut sel plasma lebih dari 2x109/l pada darah tepi, tidak ada riwayat mieloma multipel, dan gambaran klinis yang agresif.
Kata Kunci: Leukemia sel plasma, mieloma multipel, sel plasma

Downloads

Download data is not yet available.

References

Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma Cell Leukemia: Consensus Statement on Diagnostic Requirements, Response Criteria and Treatment Recommendations by the International Myeloma Working Group. Leukemia. 2013; 27(4): 780-791

Dispenzieri A, Lacy MQ, and Greipp PR. Multiple Mieloma. In: Greer JP, Foerster J, Rodgers GM, et al (Eds). Wintrobe's Clinical Hematology 12th Edition. Philadelphia-USA: Lippincott Williams & Wilkins. 2009: 2414-2415.

Albarracin F and Fonseca R. Plasma Cell Leukemia. Blood Reviews. 2011; 25(3): 107-112.

Chokshi MH, Baji SN, and Gandhi AS. Plasma Cell Leukemia: A Comprehensive Analysis of Clinical

& Pathological Features of 7 Cases. International Journal of Medical Science and Public Health. 2014; 3(1): 6-9.

Lebovic D, Zhang L, Alsina M, et al. Clinical Outcomes of Patients with Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single Institution Experience. Clinical Lymphoma, Myeloma, and Leukemia. 2011; 11(6): 507-511.

Fonseca D, Ahmed F, Murthy S, and Rajappa S. Plasma Cell Leukemia, Case Report. International Journal of Pharma and Bio Sciences. 2012; 3(3): 476-481.

van de Donk NWCJ, Lokhorst HM, Anderson KC, and Richardson PG. How I Treat Plasma Cell Leukemia. Blood. 2012; 120(12): 2376-2389.

Kraj M, Kopeć-Szlęzak J, Pogłód R, and Kruk B. Flow Cytometric Immunophenotypic Characteristics of 36 Cases of Plasma Cell Leukemia. Leukemia Research. 2011; 35(2): 169-176.

Johnson MR, Del Carpio-Jayo D, Lin P, et al. Primary Plasma Cell Leukemia: Morphologic, Immunophenotypic, and Cytogenetic Features of 4 Cases Treated with Chemotherapy and Stem Cell Transplantation. Annals of Diagnostic Pathology. 2006; 10(5): 263–268.

Kumar S, Kimlinger T, and Morice W. Immunophenotyping in Multiple Myeloma and Related Plasma Cell Disorders. Best Practice & Research. Clinical Haematology. 2010; 23(3): 433–451.

Dimopoulos MA, Kastritis E, Rosinol L, Blade J and Ludwig H. Pathogenesis and Treatment of Renal Failure in Multiple Myeloma. Leukemia. 2008; 22(8): 1485–1493.

Heher EC, Rennke HG, Laubach JP, and Richardson PG. Kidney Disease and Multiple Myeloma. Clinical Journal of the American Society of Nephrology. 2013; 8(11): 2007-2017.

Oyajobi BO. Multiple Myeloma/Hypercalcemia: Review. Arthritis Research & Therapy. 2007; 9(Suppl 1): S4.

Dadu T, Rangan A, Handoo A, and Bhargava M. Primary Non-Secretory Plasma Cell Leukemia with Atypical Morphology-A Case Report. Indian Journal of Hematology and Blood Transfusion. 2009; 25(2): 81–83

Giuliani N, Colla S, and Rizzoli V. Update on the Pathogenesis of Osteolysis in Multiple Mieloma Patients. Acta Bio-Medica: Atenei Parmensis. 2004; 75(3): 143-152.

Giuliani N, Rizzoli V, and Roodman GD. Multiple Myeloma Bone Disease: Pathophysiology of Osteoblast Inhibition. Blood. 2006; 108(13): 3992-3996.

Downloads

Published

2016-12-30

Issue

Section

Case Report